Bridge patients, clinicians and researchers to increase our knowledge of lobular breast disease and promote research to advances in prevention, diagnosis, treatment and follow-up care.


The Lobular Breast Cancer Alliance (LBCA) was formed by advocates who attended the First International Lobular Breast Cancer Symposium at the University of Pittsburgh Cancer Institute in 2016. The symposium underscored that lobular beast cancer is understudied, and that current standard of care treatments and protocols may not always be the best option for patients with lobular disease. Patient advocates, with support from researchers and clinicians, formed LBCA to advance substantive research into ILC, refine screening and treatments and enhance patient and provider education.

Lack of research and low visibility of ILC within the breast cancer world negatively impact patient care and outcomes. LBCA hopes to close these gaps, so patients have quality and consistent information to inform their decisions and ILC is elevated within the research and larger breast cancer community to receive the funding and attention needed to improve patient care and survival.